Scynexis

Squarepoint Ops LLC bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 43,859 shares of the company’s stock, valued at approximately $53,000. Squarepoint Ops LLC owned approximately 0.12% of SCYNEXIS as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors and hedge funds have also bought and sold shares of SCYX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in SCYNEXIS by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 195,393 shares of the company’s stock worth $236,000 after buying an additional 35,233 shares during the last quarter. Millennium Management LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $31,000. Jane Street Group LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $32,000. Northern Trust Corp grew its position in SCYNEXIS by 51.9% during the fourth quarter. Northern Trust Corp now owns 153,518 shares of the company’s stock worth $186,000 after buying an additional 52,466 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in SCYNEXIS during the fourth quarter worth approximately $25,000. Institutional investors own 54.37% of the company’s stock. Analysts Set New Price Targets Separately, Wall Street Zen started coverage on SCYNEXIS in a research report on Friday, May 16th. They set a “sell” rating on the stock. View Our Latest Analysis on SCYX SCYNEXIS Stock Performance Shares of SCYX stock opened at $0.88 on Wednesday. The stock’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.03. The company has a market cap of $34.42 million, a PE ratio of -1.19 and a beta of 1.65. SCYNEXIS, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $2.29. SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.14 million. About SCYNEXIS (Free Report) SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.» Mehr auf defenseworld.net

JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy following IV echinocandin for invasive candidiasis, a life-threatening infection. The study had been on hold due to concerns about potential cross-contamination in light of draft U.S. Food and Drug Administration (FDA) guidance regarding manufacturing a non-antibiotic beta-lactam (ezetimibe) at the same site as ibrexafungerp. The study has resumed following the manufacture of new clinical supplies at another site and the lifting of the clinical hold by the FDA. If the study is successful and approval for this indication is granted by the FDA, it will give healthcare providers the opportunity to step-down their patients to a non-azole oral therapy that retains the Mechanism of Action (glucan synthase inhibition) of the IV-only echinocandins, which are the gold standard for treatment of invasive Candida infections. SCYNEXIS's position is that the dosing of this first new patient triggers a $10 million payment from partner GSK, with another $20 million payment to be triggered by the six-month anniversary of dosing. As previously disclosed, there is a disagreement between SCYNEXIS and GSK regarding the resumption of the MARIO Study and GSK's responsibility for paying these milestones. SCYNEXIS is working to resolve the disagreement.» Mehr auf globenewswire.com

JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2024.» Mehr auf globenewswire.com